Table 3.
Incremental Cost-Effectiveness Ratio: icodec compared to degludec
| Basal insulins | Δ Cost | Δ Utilities | ICER |
|---|---|---|---|
| Icodec | – €4.83 | +0.023 | Icodec dominant |
| Degludec |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.